Shanghai Obstetrics and Gynecology Hospital, Fudan University Shanghai College of Medicine, Shanghai, China.
Hum Reprod. 2017 Apr 1;32(4):794-810. doi: 10.1093/humrep/dex014.
Do platelets have any role in the reduced cytotoxicity of natural killer (NK) cells in endometriosis?
Platelets impair NK cell reactivity and function in endometriosis through multiple mechanisms.
Platelets play an important role in the development of endometriosis, and platelet-derived transforming growth factor-β1 (TGF-β1) suppresses the expression of NK Group 2, Member D (NKG2D) on NK cells, resulting in reduced cytotoxicity in women with endometriosis.
STUDY DESIGN SIZE, DURATION: Experiments on mice with induced endometriosis in which either platelets, NK cells or both were depleted and controls (none depleted). In vitro experiments with NK cells, platelets and, as target cells, endometriotic epithelial cell and endometrial stromal cell lines.
PARTICIPANTS/MATERIALS SETTING METHODS: Immunohistochemistry analysis of ectopic endometrial tissues from mice with induced endometriosis receiving either platelet depletion (PD), NK cell depletion, or both or none. Immunofluorescence, flow cytometry and gene expression analysis for major histocompatibility complex class I (MHC-I) expression in target cells. Cytotoxicity and degranulation assays and the measurement of interferon (IFN)-γ secretion for the evaluation of NK cytotoxicity. Flow cytometry and gene expression for the expression of NK cell receptors.
PD resulted in significantly reduced lesion weight in mice with induced endometriosis, but NK cell depletion as well as concomitant platelet and NK cell depletion increased the weight, suggesting that the anti-endometriosis effect of PD is mediated, at least in part, by increased NK cell cytotoxicity against endometriotic cells. Co-incubation of target cells with platelets resulted in rapid platelet coating as well as increased MHC-I expression in these cells, effectively providing a cloak of 'pseudo-self' to these cells to shield against NK cell lysis. It also reduced the expression of NKG2D ligands MICA and MICB and reduced the NK cell cytotoxicity. In addition, co-incubation of NK cells with platelets impaired the NK cell cytotoxicity as well. This impaired NK cell cytotoxicity was not due to the increased NK cell apoptosis, but, rather, through reduced NK cell degranulation and IFN-γ production, and reduced expression of activating receptors NKG2D and NKp46 and increased expression of inhibitory receptor KIR2DL1 in NK cells. Inhibition of TGF-β1 signaling partially restored the aberrant expression of NKG2D, NKp46 and KIR2DL1, and partially restored the impaired NK cell cytotoxicity induced by activated platelets and their releasate.
Not applicable.
This study is confined by the limitation of animal and in vitro experimentation and the lack of direct human data.
Anti-platelet treatment holds promise in treating endometriosis.
STUDY FUNDING/COMPETING INTERESTS: The National Natural Science Foundation of China (81471434 to S.W.G., 81270676 to S.W.G., 81370695 to X.S.L. and 81671436 to X.S.L). None of the authors has anything to disclose.
血小板在子宫内膜异位症中自然杀伤(NK)细胞细胞毒性降低中起作用吗?
血小板通过多种机制损害子宫内膜异位症中 NK 细胞的反应性和功能。
血小板在子宫内膜异位症的发展中起重要作用,血小板衍生的转化生长因子-β1(TGF-β1)抑制 NK 细胞上的 NK 组 2,成员 D(NKG2D)的表达,导致子宫内膜异位症妇女的细胞毒性降低。
研究设计、大小和持续时间:在诱导子宫内膜异位症的小鼠中进行实验,其中血小板、NK 细胞或两者均被耗尽,对照组(均未耗尽)。体外实验用 NK 细胞、血小板和作为靶细胞的子宫内膜异位上皮细胞和子宫内膜基质细胞系。
参与者/材料设置方法:对接受血小板耗竭(PD)、NK 细胞耗竭或两者均接受或不接受治疗的诱导子宫内膜异位症的小鼠的异位子宫内膜组织进行免疫组织化学分析。靶细胞中主要组织相容性复合体 I(MHC-I)表达的免疫荧光、流式细胞术和基因表达分析。用于评估 NK 细胞细胞毒性的细胞毒性和脱颗粒测定以及干扰素(IFN)-γ分泌的测量。用于 NK 细胞受体表达的流式细胞术和基因表达。
PD 导致诱导子宫内膜异位症的小鼠的病变重量显著减轻,但 NK 细胞耗竭以及同时的血小板和 NK 细胞耗竭增加了病变重量,表明 PD 的抗子宫内膜异位症作用至少部分是由增加的 NK 细胞对子宫内膜异位细胞的细胞毒性介导的。靶细胞与血小板共同孵育会导致血小板迅速包裹以及这些细胞中 MHC-I 的表达增加,从而有效地为这些细胞提供“伪自身”的保护,以防止 NK 细胞溶解。它还降低了 NKG2D 配体 MICA 和 MICB 的表达,并降低了 NK 细胞的细胞毒性。此外,NK 细胞与血小板共同孵育也会损害 NK 细胞的细胞毒性。这种受损的 NK 细胞细胞毒性不是由于 NK 细胞凋亡增加所致,而是由于 NK 细胞脱颗粒和 IFN-γ产生减少,以及 NK 细胞上激活受体 NKG2D 和 NKp46 的表达减少和抑制性受体 KIR2DL1 的表达增加所致。TGF-β1 信号转导的抑制部分恢复了异常表达的 NKG2D、NKp46 和 KIR2DL1,并部分恢复了激活的血小板及其释放物诱导的受损的 NK 细胞细胞毒性。
不适用。
局限性/谨慎原因:本研究受到动物和体外实验的限制以及缺乏直接的人类数据的限制。
抗血小板治疗有望用于治疗子宫内膜异位症。
研究资金/利益冲突:中国国家自然科学基金(81471434 给 S.W.G.,81270676 给 S.W.G.,81370695 给 X.S.L.和 81671436 给 X.S.L.)。作者均无任何利益冲突。